Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts expect Cencora (COR) to post quarterly earnings of $4.37 per share in its upcoming report, which indicates a year-over-year increase of 9.3%. Revenues are expected to be $84.89 billion, up 5.2% from the year-ago quarter.

Over the last 30 days, there has been an upward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

Given this perspective, it's time to examine the average forecasts of specific Cencora metrics that are routinely monitored and predicted by Wall Street analysts.

The average prediction of analysts places 'Revenue- Total U.S. Healthcare Solutions' at $75.00 billion. The estimate suggests a change of +2.9% year over year.

Analysts' assessment points toward 'Revenue- Total International Healthcare Solutions' reaching $7.79 billion. The estimate points to a change of 0% from the year-ago quarter.

The consensus estimate for 'Operating income- International Healthcare Solutions' stands at $158.45 million. Compared to the current estimate, the company reported $156.22 million in the same quarter of the previous year.

The combined assessment of analysts suggests that 'Operating income- U.S. Healthcare Solutions' will likely reach $940.87 million. Compared to the present estimate, the company reported $901.79 million in the same quarter last year.

Shares of Cencora have experienced a change of +5.3% in the past month compared to the -0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), COR is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research